Clinical trial · Observational
EffectiveNess of Low-dose Aspirin in Prevention of Cancer in the Stomach and Oesophagus (GastrointEstinal Cancer Prevention) - United Kingdom ("ENgAGE - UK"): Study to Evaluate the Risk of Cancer in the Stomach and Oesophagus Among New Users of Low-dose Aspirin Using the THIN Database in the UK
Effectiveness of Low-dose Aspirin in Gastrointestinal Cancer Prevention -United Kingdom ("ENgAGE - UK"): A Cohort Study on the Risk of Gastric and Oesophageal Cancer Among New Users of Low-dose Aspirin Using the THIN Database in the UK
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Researchers already did studies in low-dose Aspirin for the prevention of heart and blood vessels disease and for the prevention of cancer of the colorectum. In this study, they want to learn whether an effect for the prevention of oesophagus cancer and stomach cancer goes along with the use of low-dose ASA on patients taking this medicine for the prevention of heart and blood vessels disease compared to non-use. To find this out electronic medical records stored in primary care database in the UK, The Health Improvement Network (THIN), will be used.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prevention of Oesophagus Cancer and Stomach Cancer | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acetylsalicylic Acid(BAYE4465, Aspirin ) | Drug | Aspirin | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- Low-dose ASA cohort
- description
- A person is identified as newly exposed to low-dose ASA, he/she will become member of new user low-dose ASA cohort and that date will be the start date for outcome follow-up.
- interventionNames
- Drug: Acetylsalicylic Acid(BAYE4465, Aspirin )
- label
- Comparison unexposed cohort
- description
- When a member of new user low-dose ASA cohort is confirmed, one comparison member will be confirmed also from the source population not yet censored on that day (start date) and with the same distribution of matching factors (age, sex, time interval since entry date and number of PCP visits in the year prior to start date) of its low-dose ASA pair with the only difference of being free of ASA on start date.
Primary outcomes (3)
- measure
- Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA overall compared to non-use
- timeFrame
- Retrospective analysis between 1-Jan-2005 and 31-Dec-2017
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 40-89 years * Enrolled with the PCP for at least 2 years * To have a history of computerized prescriptions in THIN for at least 1 year prior to start date Exclusion Criteria: * To be exposed to low-dose ASA before entering in the study * Having a diagnosis of any cancer before entering in the study
References
Publications (0)
Data not yet available